HAPPE Spine Announces FDA Clearance for the INTEGRATE™-C Interbody Fusion System
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachmenton
NASDAQ celebrates Shoulder Innovations
